AASLD-FDA-NIH-PhRMA Hepatotoxicity Steering Group Meeting, 2006 Presentations: Update on the DILIN
Naga Chalasani, MD
Indiana University School of Medicine
Update on the DILIN [PDF]
The Drug Induced Liver Injury Network (DILIN) comprises of 5 clinical centers and a data coordinating center. The DILIN is conducting a retrospective study and a prospective study of patients who have had liver injury caused by medications or herbals. The retrospective study involves recruiting individuals who have had DILI due to isoniazid, amox/clavulanate, valproate or phenytoin. Thus far, we have recruited more than 40 subjects into the retrospective study. The prospective study is recruiting individuals with DILI caused by any medication or herbal. In order to be enrolled into the prospective study, individuals must have certain degree of biochemical abnormalities and competing causes be excluded. More than 140 patients have been enrolled into the prospective study. During the presentation, the speaker will present some data related to patient characteristics and the patterns of liver injury. The speaker will present the data related to samples collected and plans for recruiting controls. The speaker will also discuss issues related to difficulties in subject recruitment and in identifying cases during the acute injury phase.
Naga Chalasani was educated at the Andhra Loyola College in India (biology 1979-81) and the Kakatiya Medical College (MB, BS 1988), after which he served as an internal medical resident at Emory University in Atlanta (1991-4). He followed with a fellowship in gastroenterology and hepatology at Emory (1994-7). He joined Indiana University Hospital in Indianapolis (IN) in 1997, where he currently serves as an associate professor of medicine in the Divisions of Gastroenterology/Hepatology and the Division of Clinical Pharmacology. He was elected to Alpha Omega Alpha, 1993; received the Dupont Young Investigator’s Award 1993; and the IUSM Young Investigator of the Year, 2002. He is the PI for the NIDDK-funded DILIN Clinical Center and NASH CRN Clinical Center at Indiana University.